{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:12:08Z","timestamp":1770750728401,"version":"3.50.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-016"],"award-info":[{"award-number":["2022-PUMCH-B-016"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0506800"],"award-info":[{"award-number":["2023ZD0506800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-02105-w","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:19:23Z","timestamp":1767032363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management for prolactinomas of postmenopausal female patients: a retrospective single-center study"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoxue","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-0398","authenticated-orcid":false,"given":"Linjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5172-6870","authenticated-orcid":false,"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"12","key":"2105_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement (published correction appears in Nat rev Endocrinol. 2024;20(1):62. Doi: 10.1038\/s41574-023-00916-2). Nat Rev Endocrinol. 2023;19(12):722\u201340. https:\/\/doi.org\/10.1038\/s41574-023-00886-5.","journal-title":"Nat Rev Endocrinol"},{"issue":"16","key":"2105_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/jama.2023.5444","volume":"329","author":"NA Tritos","year":"2023","unstructured":"Tritos NA, Miller KK, Diagnosis, Management of Pituitary Adenomas. Rev JAMA. 2023;329(16):1386\u201398. https:\/\/doi.org\/10.1001\/jama.2023.5444.","journal-title":"Rev JAMA"},{"issue":"2","key":"2105_CR3","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2105_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","volume":"54","author":"S Karunakaran","year":"2001","unstructured":"Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001;54(3):295\u2013300. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01190.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2105_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1590\/2359-3997000000138","volume":"60","author":"MS Mallea-Gil","year":"2016","unstructured":"Mallea-Gil MS, Manavela M, Alfieri A, et al. Prolactinomas: evolution after menopause. Arch Endocrinol Metab. 2016;60(1):42\u20136. https:\/\/doi.org\/10.1590\/2359-3997000000138.","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2105_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/cen.13765","volume":"89","author":"S Santharam","year":"2018","unstructured":"Santharam S, Fountas A, Tampourlou M, et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf) Sep. 2018;89(3):346\u201353. https:\/\/doi.org\/10.1111\/cen.13765.","journal-title":"Clin Endocrinol (Oxf) Sep"},{"issue":"2\u20133","key":"2105_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12672-019-00363-4","volume":"10","author":"R Indirli","year":"2019","unstructured":"Indirli R, Ferrante E, Sala E, Giavoli C, Mantovani G, Arosio M. Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm Cancer. 2019;10(2\u20133):120\u20137. https:\/\/doi.org\/10.1007\/s12672-019-00363-4.","journal-title":"Horm Cancer"},{"key":"2105_CR8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf152","author":"SM Constantinescu","year":"2025","unstructured":"Constantinescu SM, Nava CM, Chasseloup F, Alexopoulou O, Chanson P, Maiter D. Menopause has a beneficial influence on the evolution of prolactinomas. A study of 99 patients. J Clin Endocrinol Metab. 2025. https:\/\/doi.org\/10.1210\/clinem\/dgaf152.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2105_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s0015-0282(97)81368-4","volume":"67","author":"Y Maor","year":"1997","unstructured":"Maor Y, Berezin M. Hyperprolactinemia in postmenopausal women. Fertil Steril. 1997;67(4):693\u20136. https:\/\/doi.org\/10.1016\/s0015-0282(97)81368-4.","journal-title":"Fertil Steril"},{"issue":"3","key":"2105_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","volume":"47","author":"I Shimon","year":"2014","unstructured":"Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014;47(3):889\u201394. https:\/\/doi.org\/10.1007\/s12020-014-0259-1.","journal-title":"Endocrine"},{"issue":"5","key":"2105_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/cen.13399","volume":"87","author":"S Santharam","year":"2017","unstructured":"Santharam S, Tampourlou M, Arlt W, et al. Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin Endocrinol (Oxf). 2017;87(5):508\u201314. https:\/\/doi.org\/10.1111\/cen.13399.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2105_CR12","doi-asserted-by":"publisher","unstructured":"Duralde ER, Sobel TH, Manson JE. Management of perimenopausal and menopausal symptoms [published correction appears in BMJ. 2023;382:p1977. doi: 10.1136\/bmj.p1977.] [published correction appears in BMJ. 2023;383:p2636. https:\/\/doi.org\/10.1136\/bmj.p2636. BMJ. 2023;382:e072612. Published 2023 Aug 8. https:\/\/doi.org\/10.1136\/bmj-2022-072612.","DOI":"10.1136\/bmj.p2636"},{"issue":"19","key":"2105_CR13","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1016\/j.cell.2023.08.016","volume":"186","author":"SR Davis","year":"2023","unstructured":"Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause-Biology, consequences, supportive care, and therapeutic options. Cell. 2023;186(19):4038\u201358. https:\/\/doi.org\/10.1016\/j.cell.2023.08.016.","journal-title":"Cell"},{"issue":"2","key":"2105_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s12020-023-03678-z","volume":"84","author":"E Varaldo","year":"2024","unstructured":"Varaldo E, Cuboni D, Prencipe N, et al. Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia? Endocrine. 2024;84(2):670\u20136. https:\/\/doi.org\/10.1007\/s12020-023-03678-z.","journal-title":"Endocrine"},{"issue":"1","key":"2105_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-019-00989-1","volume":"23","author":"P Souteiro","year":"2020","unstructured":"Souteiro P, Belo S, Carvalho D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary. 2020;23(1):38\u201344. https:\/\/doi.org\/10.1007\/s11102-019-00989-1.","journal-title":"Pituitary"},{"issue":"2","key":"2105_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388. https:\/\/doi.org\/10.1210\/jc.2010-1692.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2105_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","volume":"59","author":"MY Xia","year":"2018","unstructured":"Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50\u201361. https:\/\/doi.org\/10.1007\/s12020-017-1444-9.","journal-title":"Endocrine"},{"issue":"1","key":"2105_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P, J\u00f8rgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43\u201351. https:\/\/doi.org\/10.1210\/jc.2009-1238.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2105_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","volume":"18","author":"J Hu","year":"2015","unstructured":"Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary. 2015;18(5):745\u201351. https:\/\/doi.org\/10.1007\/s11102-014-0617-2.","journal-title":"Pituitary"},{"issue":"9","key":"2105_CR20","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1210\/jcem.81.9.8784065","volume":"81","author":"O Serri","year":"1996","unstructured":"Serri O, Noiseux D, Robert F, Hardy J. Lactotroph hyperplasia in an Estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab. 1996;81(9):3177\u20139. https:\/\/doi.org\/10.1210\/jcem.81.9.8784065.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2105_CR21","first-page":"198","volume":"113","author":"RV Lloyd","year":"1983","unstructured":"Lloyd RV. Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. Am J Pathol. 1983;113(2):198\u2013206.","journal-title":"Am J Pathol"},{"issue":"1\u20132","key":"2105_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2005.04.008","volume":"239","author":"S Kansra","year":"2005","unstructured":"Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. Differential effects of Estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005;239(1\u20132):27\u201336. https:\/\/doi.org\/10.1016\/j.mce.2005.04.008.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2105_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11060-013-1351-8","volume":"116","author":"L Cao","year":"2014","unstructured":"Cao L, Gao H, Gui S, et al. Effects of the Estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models. J Neurooncol. 2014;116(3):523\u201331. https:\/\/doi.org\/10.1007\/s11060-013-1351-8.","journal-title":"J Neurooncol"},{"issue":"12","key":"2105_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1530\/ERC-22-0168","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ma L, Dong S, et al. TLR4 Inhibition suppresses growth in oestrogen-induced prolactinoma models. Endocr Relat Cancer. 2022;29(12):703\u201316. https:\/\/doi.org\/10.1530\/ERC-22-0168. Published 2022 Nov 7.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2105_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","volume":"14","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Mancini T, Mormando M, et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. 2011;14(4):299\u2013306. https:\/\/doi.org\/10.1007\/s11102-011-0293-4.","journal-title":"Pituitary"},{"issue":"9","key":"2105_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJM198608283150903","volume":"315","author":"A Klibanski","year":"1986","unstructured":"Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1986;315(9):542\u20136. https:\/\/doi.org\/10.1056\/NEJM198608283150903.","journal-title":"N Engl J Med"},{"issue":"5","key":"2105_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","volume":"64","author":"J Schlechte","year":"1987","unstructured":"Schlechte J, el-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1987;64(5):1021\u20136. https:\/\/doi.org\/10.1210\/jcem-64-5-1021.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2105_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/HYPERTENSIONAHA.109.132100","volume":"54","author":"GA Georgiopoulos","year":"2009","unstructured":"Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension. 2009;54(1):98\u2013105. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.132100.","journal-title":"Hypertension"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-02105-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:19:24Z","timestamp":1767032364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-025-02105-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-02105-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Declaration of Helsinki, the study protocol was approved by the Institutional Review Board and Ethics Committee of Peking Union Medical College Hospital (Ethical audit number: I-24PJ1285). The informed consent of all participants has been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}